Abaloparatide for Osteoporosis in Knee Replacement
Trial Summary
What is the purpose of this trial?
The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.
Research Team
Neil Binkley, MD
Principal Investigator
University of Wisconsin, Madison
Eligibility Criteria
This trial is for post-menopausal women and men aged 55 or older with osteoporosis, scheduled for knee replacement surgery at the University of Wisconsin. They must have normal blood tests, take daily calcium and vitamin D3, and not have had certain treatments affecting bone metabolism. People with chronic diseases or a history of cancer (except some skin cancers) in the past five years are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-operative Treatment
Participants receive daily abaloparatide therapy starting 3 months before total knee arthroplasty
Post-operative Treatment
Participants continue daily abaloparatide therapy after total knee arthroplasty
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Abaloparatide
Abaloparatide is already approved in United States, European Union, Japan for the following indications:
- Osteoporosis in postmenopausal women at high risk of fracture
- Osteoporosis in men at high risk of fracture
- Osteoporosis in postmenopausal women at increased risk of fracture
- Osteoporosis in patients at high risk of fracture
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
Radius Health, Inc.
Industry Sponsor